Lumos Diagnostics (ASX:LDX) has broadened access to its flagship rapid diagnostic test, FebriDx, through a new distribution agreement with Amtech Medical, part of the Australasian healthcare alliance YesGroup.
The partnership complements Lumos’ existing agreement with Henry Schein and will significantly expand the availability of FebriDx to clinicians across Australia and New Zealand.
YesGroup, which unites Yes Medical and Amtech Medical, is a major provider of medical and safety supplies in the region, employing over 150 staff and offering more than 25,000 product lines. Its established presence and trusted networks position the group as a strong partner for Lumos in driving the adoption of innovative diagnostic tools.
FebriDx is a point-of-care test that delivers results in about 10 minutes, enabling healthcare professionals to differentiate between bacterial and viral respiratory infections quickly. By supporting more accurate clinical decision-making, the test has the potential to reduce unnecessary antibiotic prescribing and help combat antimicrobial resistance.
“YesGroup are proud to partner with Lumos Diagnostics to bring FebriDx to more clinicians across Australia and New Zealand,” said Craig Anderson, CEO of YesGroup. “With FebriDx, clinicians gain access to a rapid, reliable tool that supports smarter prescribing decisions and strengthens frontline care.”
Doug Ward, CEO of Lumos Diagnostics, said the agreement marks an important milestone. “With YesGroup’s reach and long-standing presence in the healthcare market, alongside our existing agreement with Henry Schein, we are well-positioned to make FebriDx more widely accessible to clinicians.”
The expanded distribution footprint comes as healthcare systems continue to seek faster, more effective diagnostic solutions to improve patient outcomes and reduce pressures on frontline care.
Alongside its commercial progress, Lumos also confirmed it has completed documentation for a $5 million secured loan facility with major shareholders Tenmile Ventures and Ryder Capital Management. The loan will provide working capital flexibility, if required, as the company progresses towards a CLIA waiver from the US FDA for FebriDx.
Under the agreement, Tenmile and Ryder Capital will each receive 7.5 million Lumos shares in satisfaction of establishment and service fees. The company also announced the termination of its prior convertible note arrangement with Lind Global Fund II and SBC Global Investment Fund, including the unused second tranche of $4 million.
Ward said the new facility strengthens Lumos’ ability to advance its strategy. “Securing this facility provides Lumos with the flexibility to continue progressing towards CLIA waiver and the broader commercialisation of FebriDx, while minimising equity dilution for our shareholders. We are grateful for the ongoing commitment of Tenmile and Ryder Capital, whose support has been pivotal in enabling us to execute on our strategy and maintain momentum at this important stage.”